Evidence map›Paper›PMID 35942997›Full record

ArticleArchives of Iranian medicine2022

Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women.

Lobna Bouzidi, Saadia Makni, Jihen Feki, Rim Kallel, Soumaya Graja, Naourez Gouiaa, Tahya Sellami-Boudawara, Manel Mellouli

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of Iranian medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lobna BouzidiDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.ORCID 0000-0001-7651-4671
Saadia MakniDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Jihen FekiDepartment of Medical Oncology, University Hospital Habib Bourguiba, Sfax, Tunisia.
Rim KallelDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Soumaya GrajaDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Naourez GouiaaDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Tahya Sellami-BoudawaraDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Manel MellouliDepartment of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
University of Sfax · TNHopital Universitaire Habib Bourguiba · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer represents the most frequent cancer and cause of death in women worldwide and in Tunisia. Cyclin D1 is a gene of cell cycle regulation. It represents a potential oncogene in invasive breast cancer; however; the results are conflicting. We performed a retrospective study aiming to analyze the prognostic impact of cyclin D1 expression in patients with invasive breast carcinoma of no special type and its relation with clinical-pathological features.

methodsOne hundred cases of invasive breast carcinoma of no special type diagnosed between 2009 and 2011 were included in this study. Immunohistochemical (IHC) staining was performed for cyclin D1 in all cases. Results were analyzed statistically.

resultsCyclin D1 positivity was seen in 74 cases (74%), of which 32 cases (32%) showed strong immunoreactivity. Cyclin D1 staining was statistically significantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity (

conclusionThese results confirm that cyclin D1 overexpression can be employed as a beneficial prognostic marker and suggest that anti-cyclin D1 therapy may be efficient, especially for ER positive tumors.

Indexed as

Breast NeoplasmsReceptors, EstrogenBiomarkers, TumorCyclin D1Disease-Free SurvivalFemaleHumansPrognosisRetrospective StudiesBiomarkers, TumorCCND1 protein, humanCyclin D1Receptors, EstrogenBreast cancerCyclin D1Estrogen receptorProgesterone receptorPrognosis

Identifiers

PMID35942997
PMCPMC11897875
OpenAlexW4293108183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.